{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:29:36Z","timestamp":1794680976431,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neonatal hyperbilirubinemia (NHb) results from increased total serum bilirubin and is a common reason for admission and readmission amongst newborn infants born in North America. The use of intravenous immunoglobulin (IVIG) therapy for treating NHb has been widely debated, and the current incidence of NHb and its therapies remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using national and provincial databases, a population-based retrospective cohort study of infants born in Ontario from April 2014 to March 2018 was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 533,084 infants born in Ontario at \u226535 weeks gestation, 29,756 (5.6%) presented with NHb. Among these infants, 80.1\u201388.2% received phototherapy, 1.1\u20132.0% received IVIG therapy and 0.1\u20130.2% received exchange transfusion (ET) over the study period. Although phototherapy was administered (83.0%) for NHb, its use decreased from 2014 to 2018 (88.2\u201380.1%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Similarly, the incidence of IVIG therapy increased from 71 to 156 infants (1.1\u20132.0%) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) and a small change in the incidence of ET (0.2\u20130.1%) was noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IVIG therapy is increasingly being used in Ontario despite limited studies evaluating its use. The results of this study could inform treatment and management protocols for NHb.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impacts<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Clinically significant neonatal hyperbilirubinemia still occurs in Ontario, with an increasing number of infants receiving Intravenous Immunoglobulin G (IVIG) therapy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>IVIG continues to be used at increasing rates despite inconclusive evidence to recommend its use.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This study highlights the necessity of a future prospective study to better determine the effectiveness of IVIG use in treating neonatal hyperbilirubinemia, especially given the recent shortage in IVIG supply in Ontario.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The results of this study could inform treatment and management protocols for neonatal hyperbilirubinemia.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-023-02712-0","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T12:04:34Z","timestamp":1690286674000},"page":"2092-2097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia"],"prefix":"10.1038","volume":"94","author":[{"given":"Saisujani","family":"Rasiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thivia","family":"Jegathesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakeshkumar S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Sgro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"2712_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1515\/JPM.1999.037","volume":"27","author":"AK Brown","year":"1999","unstructured":"Brown, A. K. et al. Factors relating to readmission of term and near-term neonates in the first two weeks of life. Early Discharge Survey Group of the Health Professional Advisory Board of the Greater New York Chapter of the March of Dimes. J. Perinat. Med. 27, 263 (1999).","journal-title":"J. Perinat. Med."},{"key":"2712_CR2","first-page":"2","volume":"2011","author":"P Woodgate","year":"2011","unstructured":"Woodgate, P. & Jardine, L. A. Neonatal jaundice. BMJ Clin. Evid. 2011, 2 (2011).","journal-title":"BMJ Clin. Evid."},{"key":"2712_CR3","first-page":"e381","volume":"59","author":"PC Mateo","year":"2013","unstructured":"Mateo, P. C., Lee, K. S., Barozzino, M. & Sgro, M. Management of neonatal jaundice varies by practitioner type. Can. Fam. Physician 59, e381 (2013).","journal-title":"Can. Fam. Physician"},{"key":"2712_CR4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1542\/peds.2003-0575-F","volume":"114","author":"American Academy of Pediatrics.","year":"2004","unstructured":"American Academy of Pediatrics. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 114, 307 (2004).","journal-title":"Pediatrics"},{"key":"2712_CR5","doi-asserted-by":"publisher","first-page":"c2409","DOI":"10.1136\/bmj.c2409","volume":"340","author":"J Rennie","year":"2010","unstructured":"Rennie, J., Burman-Roy, S. & Murphy, M. S. Neonatal jaundice: summary of nice guidance. BMJ 340, c2409 (2010).","journal-title":"BMJ"},{"key":"2712_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1503\/cmaj.060328","volume":"175","author":"M Sgro","year":"2006","unstructured":"Sgro, M., Campbell, D. & Shah, V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. Can. Med. Assoc. J. 175, 589 (2006).","journal-title":"Can. Med. Assoc. J."},{"key":"2712_CR7","doi-asserted-by":"publisher","first-page":"1B","DOI":"10.1093\/pch\/12.suppl_B.1B","volume":"12","author":"K Barrington","year":"2007","unstructured":"Barrington, K. & Sankaran, K. Guidelines for detection, managaement and prevention of hyperbilirubinemia in term and late preterm newborn infants. Paediatr Child Health 12, 1B\u201312B (2007).","journal-title":"Paediatr Child Health"},{"key":"2712_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jpeds.2015.12.067","volume":"171","author":"M Sgro","year":"2016","unstructured":"Sgro, M., Kandasamy, S., Shah, V., Ofner, M. & Campbell, D. Severe neonatal hyperbilirubinemia decreased after the 2007 Canadian Guidelines. J. Pediatr. 171, 43 (2016).","journal-title":"J. Pediatr."},{"key":"2712_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jpeds.2021.05.039","volume":"236","author":"TM Bahr","year":"2021","unstructured":"Bahr, T. M., Henry, E., Christensen, R. D., Minton, S. D. & Bhutani, V. K. A new hour-specific serum bilirubin nomogram for neonates \u226535 weeks of gestation. J. Pediatr. 236, 28\u201333.e1 (2021).","journal-title":"J. Pediatr."},{"key":"2712_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1651-2227.2008.00743.x","volume":"97","author":"AA Salas","year":"2008","unstructured":"Salas, A. A. & Mazzi, E. Exchange transfusion in infants with extreme hyperbilirubinemia: an experience from a developing country. Acta Paediatr. 97, 754 (2008).","journal-title":"Acta Paediatr."},{"key":"2712_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.99.5.e7","volume":"99","author":"JC Jackson","year":"1997","unstructured":"Jackson, J. C. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 99, 1 (1997).","journal-title":"Pediatrics"},{"key":"2712_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/vox.13090","volume":"116","author":"IM Ree","year":"2021","unstructured":"Ree, I. M. et al. Exchange transfusions in severe Rh\u2010mediated alloimmune haemolytic disease of the foetus and newborn: a 20\u2010year overview on the incidence, associated risks and outcome. Vox Sang 116, 990\u2013997 (2021).","journal-title":"Vox Sang"},{"key":"2712_CR13","first-page":"12","volume":"2","author":"C Zwiers","year":"2018","unstructured":"Zwiers, C., Scheffer-Rath, M. E. A., Lopriore, E., Haas, M. D. & Liley, H. G. Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst. Rev. 2, 12\u201314 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2712_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12288-012-0186-3","volume":"30","author":"S Beken","year":"2014","unstructured":"Beken, S. et al. Intravenous immunoglobulin G treatment in Abo hemolytic disease of the newborn, is it myth or real? Indian J. Hematol. Blood Transfus. 30, 12\u201315 (2014).","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"2712_CR15","first-page":"163","volume":"16","author":"AM Miqdad","year":"2004","unstructured":"Miqdad, A. M. et al. Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in Abo hemolytic disease of the newborn. J. Matern. Fetal Meonatal Med. 16, 163 (2004).","journal-title":"J. Matern. Fetal Meonatal Med."},{"key":"2712_CR16","first-page":"CD003313","volume":"6","author":"GS Alcock","year":"2002","unstructured":"Alcock, G. S. & Liley, H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst. Rev. 6, CD003313 (2002).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2712_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/tropej\/47.1.50","volume":"47","author":"G Tanyer","year":"2001","unstructured":"Tanyer, G., Siklar, Z., Dallar, Y., Yildirmak, Y. & Tiras, U. Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. J. Trop. Pediatr. 47, 53 (2001).","journal-title":"J. Trop. Pediatr."},{"key":"2712_CR18","first-page":"967","volume":"74","author":"SWIE Fekey","year":"2019","unstructured":"Fekey, S. W. I. E., El-Sharkawy, H. M., Abd-Ellatif Elsaied Ahmed, A., Abd-Ellatif Nassar, M. & Elgendy, M. M. Effect of intravenous immunoglobulin in reducing bilirubin levels in hemolytic disease of newborn. Egypt J. Hosp. Med. 74, 967 (2019).","journal-title":"Egypt J. Hosp. Med."},{"key":"2712_CR19","unstructured":"Canadian Blood Services. The National Plan for Management of Shortages of Immunoglobulin Products (Ig) \u2013 Interim Guidance. 1\u201361 (2020)."},{"key":"2712_CR20","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1542\/peds.2012-0253","volume":"130","author":"M Sgro","year":"2012","unstructured":"Sgro, M., Campbell, D. M., Kandasamy, S. & Shah, V. Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008. Pediatrics 130, e890 (2012).","journal-title":"Pediatrics"},{"key":"2712_CR21","unstructured":"BORN Ontario. Requesting Data; https:\/\/www.bornontario.ca\/en\/data\/requesting-data.aspx (2019)."},{"key":"2712_CR22","unstructured":"The Canadian Neonatal Network. About the Canadian Neonatal Network; http:\/\/www.canadianneonatalnetwork.org\/portal\/ (2009)."},{"key":"2712_CR23","unstructured":"The Canadian Neonatal Network. Abstractor\u2019s Manual; https:\/\/www.canadianneonatalnetwork.org\/portal\/Portals\/0\/CNN%20Manuals\/CNN%20Manual_20220201.pdf (2022)."},{"key":"2712_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4825-3","volume":"19","author":"S Dunn","year":"2019","unstructured":"Dunn, S. et al. Data accuracy in the Ontario Birth Registry: a chart re-abstraction study. BMC Health Serv. Res. 19, 1001 (2019).","journal-title":"BMC Health Serv. Res."},{"key":"2712_CR25","unstructured":"BORN Ontario. History; https:\/\/www.bornontario.ca\/en\/about-born\/history.aspx (2022)."},{"key":"2712_CR26","unstructured":"The Canadian Neonatal Network. The Canadian Neonatal Network; http:\/\/www.canadianneonatalnetwork.org\/portal\/ (2009)."},{"key":"2712_CR27","unstructured":"BORN Ontario. Promoting Data & Information Quality; https:\/\/www.bornontario.ca\/en\/data\/promoting-data-quality.aspx (2022)."},{"key":"2712_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12884-023-05446-3","volume":"23","author":"S Dimanlig-Cruz","year":"2023","unstructured":"Dimanlig-Cruz, S. et al. Perinatal and pediatric outcomes associated with the use of fertility treatment: a population-based retrospective cohort study in Ontario, Canada. BMC Pregnancy Childbirth 23, 1\u201315 (2023).","journal-title":"BMC Pregnancy Childbirth"},{"key":"2712_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2431-5-22","volume":"5","author":"K Aziz","year":"2005","unstructured":"Aziz, K. et al. Variations in rates of nosocomial infection among canadian neonatal intensive care units may be practice-related. BMC Pediatr. 5, 1\u201312 (2005).","journal-title":"BMC Pediatr."},{"key":"2712_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archpedi.155.3.387","volume":"155","author":"SK Lee","year":"2001","unstructured":"Lee, S. K. et al. Evidence for changing guidelines for routine screening for retinopathy of prematurity. Arch. Pediatr. Adolesc. Med. 155, 387\u2013395 (2001).","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"2712_CR31","doi-asserted-by":"publisher","first-page":"e036203","DOI":"10.1136\/bmjopen-2019-036203","volume":"10","author":"A Conway","year":"2020","unstructured":"Conway, A., Reszel, J., Walker, M. C., Grimshaw, J. M. & Dunn, S. I. Obstetrical safety indicators for preventing hospital harms in low risk births: a scoping review protocol. BMJ Open 10, e036203 (2020).","journal-title":"BMJ Open"},{"key":"2712_CR32","unstructured":"Provincial Council for Maternal and Child Health. Maternal-Child Services Report Section II: Neonatal and Obstetrical Indicators, 4 (Provincial Council for Maternal and Child Health); https:\/\/www.pcmch.on.ca\/wp-content\/uploads\/2017\/03\/2016-OHMCSR-Neonatal-and-Obstetrical-Indicators-1.pdf (2016)."},{"key":"2712_CR33","unstructured":"Provincial Council for Maternal Child Health. Ontario Hospitals, Maternal-Child Benchmarking Report. 33; http:\/\/www.pcmch.on.ca\/wp-content\/uploads\/2015\/07\/PCMCH-2014-MCBR.pdf (2014)."},{"key":"2712_CR34","unstructured":"Statistcs Canada. Fertility: Overview, 2012 to 2016; https:\/\/www150.statcan.gc.ca\/n1\/pub\/91-209-x\/2018001\/article\/54956-eng.htm (2018)."},{"key":"2712_CR35","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Estimates of Births, by Sex, Annual; https:\/\/doi.org\/10.25318\/1710001601-eng (2020).","DOI":"10.25318\/1710001601-eng"},{"key":"2712_CR36","first-page":"27","volume":"3","author":"M Khassawneh","year":"2013","unstructured":"Khassawneh, M., Rubaie, Z., Khashashneh, I., Makhlouf, F. & Alkafajei, A. Adherence with American Academy of Pediatrics Guidelines when managing neonatal jaundice in Jordan. Res. Rep. Neonatol. 3, 27\u201331 (2013).","journal-title":"Res. Rep. Neonatol."},{"key":"2712_CR37","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41372-020-0642-0","volume":"40","author":"MF Wolf","year":"2020","unstructured":"Wolf, M. F. et al. Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia. J. Perinatol. 40, 1506\u20131512 (2020).","journal-title":"J. Perinatol."},{"key":"2712_CR38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/030006059502300406","volume":"23","author":"T Dagoglu","year":"1995","unstructured":"Dagoglu, T., Ovali, F., Samangi, N. & Bengisu, E. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J. Int. Med. Res. 23, 264\u2013271 (1995).","journal-title":"J. Int. Med. Res."},{"key":"2712_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00431-010-1310-8","volume":"170","author":"M Elalfy","year":"2011","unstructured":"Elalfy, M., Elbarbary, N. & Abaza, H. Early intervenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn \u2013 a prospective randomized controlled trial. Eur. J. Pediatr. 170, 461\u2013467 (2011).","journal-title":"Eur. J. Pediatr."},{"key":"2712_CR40","first-page":"1827","volume":"27","author":"F Nasseri","year":"2006","unstructured":"Nasseri, F., Mamouri, G. A. & Babaei, H. Intravenous immunoglobulin in Abo and hemolytic disease of newborn. Saudi Med. J. 27, 1827 (2006).","journal-title":"Saudi Med. J."},{"key":"2712_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0022-3476(05)82551-X","volume":"121","author":"J Rubo","year":"1992","unstructured":"Rubo, J. et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J. Pediatr. 121, 93\u201397 (1992).","journal-title":"J. Pediatr."},{"key":"2712_CR42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1651-2227.1999.tb01085.x","volume":"88","author":"F Alpay","year":"1999","unstructured":"Alpay, F. et al. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr. 88, 216\u2013219 (1999).","journal-title":"Acta Paediatr."},{"key":"2712_CR43","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1542\/peds.2010-3242","volume":"127","author":"VEHJ Smits-Wintjens","year":"2011","unstructured":"Smits-Wintjens, V. E. H. J. et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics 127, 680\u2013686 (2011).","journal-title":"Pediatrics"},{"key":"2712_CR44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1537-2995.2012.03827.x","volume":"53","author":"MC Santos","year":"2013","unstructured":"Santos, M. C., Sa, C., Gomes, S. C. Jr, Camacho, L. A. & Moreira, M. E. The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial. Transfusion 53, 777\u2013782 (2013).","journal-title":"Transfusion"},{"key":"2712_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1542\/peds.51.2.288","volume":"51","author":"M Orzalesi","year":"1973","unstructured":"Orzalesi, M., Gloria, F., Lucarelli, P. & Bottini, E. Abo system incompatibility: relationship between direct coombs test positivity and neonatal jaundice. Pediatrics 51, 288 (1973).","journal-title":"Pediatrics"},{"key":"2712_CR46","doi-asserted-by":"publisher","first-page":"762","DOI":"10.14740\/jocmr4003","volume":"11","author":"M Al-Lawama","year":"2019","unstructured":"Al-Lawama, M., Badran, E., Elrimawi, A., Bani Mustafa, A. & Alkhatib, H. Intravenous immunoglobulins as adjunct treatment to phototherapy in isoimmune hemolytic disease of the newborn: a retrospective case-control study. J. Clin. Med. Res. 11, 762 (2019).","journal-title":"J. Clin. Med. Res."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02712-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02712-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02712-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:04:40Z","timestamp":1700651080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02712-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1038\/s41390-023-02712-0","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"5 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R., T.J., D.M.C. and M.D.S. have no conflicts of interest relevant to this article to disclose. P.S.S. is a director of the Canadian Neonatal Network (CNN), committee member of the Provincial Council of Maternal Child Health, Ontario, and a member of Maternal and Neonatal Outcomes Committee, Better Outcome and registry Network (BORN) Ontario.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research ethics board approval for this study was obtained through St. Michael\u2019s Hospital in Toronto, Ontario. Patient consent was not required as this was a retrospective cohort study. The waiver of consent fulfills the requirements as outlined in TCPS2 Article 5.5A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}